Based on recent publications, we estimate that 67,000 patients in the US and EU, combined, are currently diagnosed with acromegaly.1

Acromegaly is typically caused by benign pituitary tumors that oversecrete growth hormone, which leads to elevated levels of IGF-1, producing the clinical signs and symptoms that characterize acromegaly.2 These effects may manifest slowly over the course of a decade or more.2


Clinical Development in Acromegaly

Veldoreotide is a novel investigational product under development by Strongbridge for use in treating acromegaly.

The safety and efficacy of veldoreotide for treatment of acromegaly have not been established.


  1. Company-sponsored analysis and published research including Jakob Dal “Incidence and late prognosis of acromegaly in Denmark: preliminary data” (2010).
  2. Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol. 2012;540398. Accessed December 3, 2015.
  3. Ayuk J, Sheppard MC. Does acromegaly enhance mortality? Rev Endocr Metab Disord. 2008;9(1):33-39.
  4. Bates AS, Van’t Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med. 1993;86(5):293-299.
  5. Dekkers OM, Biermasz NR, Pereria AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93(1):61-67.
  6. Manjila S, Wu OC, Khan FR, et al. Pharmacological management of acromegaly: a current perspective. Neurosurg Focus. 2010; Oct29(4):E14.
  7. Mayo Clinic Staff. Diseases and Conditions: Acromegaly: Symptoms. Mayo Foundation for Medical Education and Research website. Accessed December 3, 2015.

© 2017 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA is a trademark of Strongbridge Biopharma plc.
KEVEYIS® is a registered trademark licensed exclusively in the US to Strongbridge Biopharma plc.
MLR010 V11 10/2017

900 Northbrook Drive, Suite 200
Trevose, PA 19053
United States
Phone: +1 610-254-9200

Privacy Statement
Comprehensive Compliance Program
California Statement of Compliance